Latest Research Highlights

Basic Tazorac Information

• INN (International Nonproprietary Name): Tazarotene
• Brand Names Available In Australia: not specified
• ATC Code: D10AD05
• Forms & Dosages: Cream and Gel 0.05% and 0.1% (tubes 15 g, 30 g, 60 g); Foam 0.1% (50 g can)
• Manufacturers In Australia: not specified
• Registration Status In Australia: not specified
• OTC / Rx Classification: Prescription (Rx) only

What are clinicians seeing from 2022 to 2025 in trials and real‑world use?

Synthesis of recent international and Australian reports shows topical tazarotene remains an effective option for inflammatory acne and plaque psoriasis.

Randomised trials from 2022–2024 indicate tazarotene 0.1% can produce faster lesion reduction than topical corticosteroids alone in some psoriasis studies.

Comparative RCTs during that period suggest tazarotene 0.1% achieved earlier clearance than adapalene for some nodulocystic acne lesions.

Foam formulations such as Fabior 0.1% showed improved adherence in young adults, largely because patients found the foam more cosmetically acceptable.

Observational data from Australia and overseas emphasise that local irritation like erythema and peeling is common.

Systemic effects are rare due to low percutaneous absorption documented in product data.

Pharmacovigilance summaries from regulators repeat a clear safety concern: teratogenicity makes pregnancy an absolute contraindication.

Australian teledermatology cohorts from 2023–25 reported similar efficacy to in‑clinic prescriptions when telehealth was supported by pharmacist counselling and education about sunscreen use.

Small comparative data indicate differences between formulations for outcomes such as time to improvement, irritation rates and patient adherence.

Clinical Effectiveness In Australia

How quickly will Australian patients see benefit and how is tazarotene tracked locally?

Evidence in Australia combines limited RCT data and real‑world registries that mirror international findings.

The Therapeutic Goods Administration classifies tazarotene under ATC D10AD05 and adverse events are captured through the DAEN system.

Tazarotene reduces comedones and inflammatory lesions with some visible improvement by four weeks and a peak effect around eight to twelve weeks for acne.

TGA registries report irritation as the most frequent adverse event and confirm low systemic exposure in topical use.

PBS coverage for tazarotene is inconsistent, with many brand and generic forms not routinely listed on the PBS.

Clinicians commonly prescribe off‑PBS or advise private purchase through community pharmacy channels.

Urban dermatology clinics report easier access and closer follow‑up, while rural patients often rely on telehealth e‑prescriptions supported by community pharmacists.

Clinical outcomes are better when sunscreen and moisturiser are co‑managed by the prescriber and pharmacist.

Table: TGA‑Labelled Indications Versus Common Off‑Label Uses

Data highlight: time‑to‑improvement commonly reported as 4 weeks for initial effect and 8–12 weeks for maximal benefit.

Indications And Expanded Uses

Which conditions are licensed and what do clinicians sometimes use tazarotene for off‑label?

• Approved Uses: Acne vulgaris in patients aged 12 years and older, and plaque psoriasis in adults (labelled indications in major markets).
• Common Off‑Label Uses: Photoageing, stubborn follicular hyperkeratosis, and adjunctive targeted therapy with topical corticosteroids in limited psoriasis.

Formulations commonly used are cream or gel at 0.05% and 0.1% strengths, with foam 0.1% available internationally.

Standard practice is once‑daily application in the evening and not to exceed treatment of more than 20% of body surface area.

Clinicians should document clinical rationale for off‑label prescribing, particularly where PBS subsidy is not available.

Definition notes: age limits are ≥12 years for acne and ≥17 years for psoriasis.

Composition And Brand Landscape

What is in each tube and which brands appear on international markets?

The active ingredient is tazarotene, the INN for this topical retinoid.

The ATC code is D10AD05, grouping it among dermatological retinoids for topical use.

International brands include Tazorac as cream and gel in 0.05% and 0.1% strengths, Zorac as gel in 0.05% and 0.1%, and Fabior as a 0.1% foam.

Typical packaging sizes are 15 g, 30 g and 60 g tubes for cream and gel, and 50 g pressurised cans for foam.

In Australia, tazarotene products are typically imported or supplied by wholesalers and availability varies by region.

Community chains such as Chemist Warehouse, Priceline and TerryWhite Chemmart commonly dispense generics or order branded imports on private script.

Short table: Formulation → Concentration → Packaging

Major suppliers internationally include Bausch Health and various generic manufacturers in the US and EU, with regional licensees in CEE markets.

Contraindications And Special Precautions

Who must avoid tazarotene and what special groups need extra care?

Absolute contraindications are hypersensitivity to tazarotene or formulation ingredients and pregnancy due to proven teratogenic risk.

Breastfeeding is a relative contraindication and chest application should be avoided where possible.

Patients with eczema or highly sensitive skin are at higher risk of irritation and should be closely monitored.

For elderly and Indigenous patients, thin skin and co‑existing dermatoses mean start at a lower strength such as 0.05% and consider a slower step‑up.

Workplace considerations: facial irritation may affect comfort when wearing PPE or working outdoors in heat.

Advise strict photoprotection because photosensitivity and increased sunburn risk are documented.

Monitoring checklist:

• Confirm pregnancy status for people of childbearing potential before starting.
• Review at 2–4 weeks for early irritation and again at 8–12 weeks for treatment response.
• For rural patients, arrange telehealth review supported by community pharmacist follow‑up.

Pregnancy risk category is category X in product information; avoid use in women who are or may become pregnant.

Dosage Guidelines

What dose should be started and how do prescribers adapt it in Australia?

Apply a thin layer once nightly to affected areas for cream and gel formulations at either 0.05% or 0.1% depending on severity and tolerance.

Foam 0.1% should be shaken well and applied as a thin layer once daily.

Do not treat more than 20% of body surface area in a single application regimen.

For adolescents aged 12 years and older use the acne dosing; psoriasis dosing is intended for adults from 17 years.

Start with 0.05% for sensitive skin, elderly patients or those concerned about irritation and increase to 0.1% if tolerated.

If a dose is missed, apply as soon as remembered unless it is near the time of the next dose and do not double apply.

Overuse increases local irritation; systemic overdose is rare given low percutaneous absorption.

Stepwise dosing checklist:

1. Confirm indication and age limit.
2. Start 0.05% nightly for sensitive skin.
3. If tolerated after 2–4 weeks, consider stepping up to 0.1% for greater effect.
4. Limit treated area to ≤20% BSA.

Prescribers seeking PBS subsidy should document clinical justification when the product is not routinely listed.

Interactions Overview

What should patients avoid combining with tazarotene?

Avoid simultaneous application of other strong topical irritants such as abrasive cleansers, astringents and using benzoyl peroxide at the same time as it may increase irritation.

Systemic drug interactions are unlikely because percutaneous absorption is low.

Caution is advised when combining with other retinoids such as oral isotretinoin due to cumulative teratogenic concerns, not because of measured pharmacokinetic interaction.

Coordinate with dermatologists before mixing tazarotene with phototherapy because photosensitivity can be increased.

There are no known food interactions, but advise reduced alcohol if the skin barrier is compromised and general smoking cessation support as smoking can impair skin healing.

Run routine e‑health interaction checks and consider TGA reports for new safety signals when prescribing.

Data highlight: systemic absorption is low, so systemic drug–drug interactions are rare, but class safety rules for retinoids around pregnancy still apply.

Cultural Perceptions And Patient Habits In Australia

What do Australian patients ask about and how do habits differ between urban and rural areas?

Price sensitivity is a common theme and many patients compare private pricing across community chains and online pharmacies.

Urban patients tend to prefer gel or foam formulations for a quicker cosmetic finish, while rural patients rely heavily on telehealth prescriptions and local pharmacist counselling due to limited specialist access.

Indigenous health services emphasise culturally safe counselling, clear expectation setting about early irritation, and scheduled follow‑up.

Younger Australians frequently consult social media and forums for peer advice, which can spread misinformation about altering concentrations or DIY mixes.

Pharmacist‑led counselling that pairs a gentle moisturiser and daily sunscreen has been shown in Australian cohorts to improve adherence.

Short table: Urban Versus Rural Care Pathways

Data highlight: telehealth programmes in Australia during 2023–25 reported comparable adherence and outcomes when pharmacist counselling and sunscreen education were included.

Availability And Pricing Patterns

How and where do Australians buy tazarotene and what can they expect to pay?

Stock and supply patterns vary regionally because many tazarotene products are imported or provided on private script.

Major chains such as Chemist Warehouse, Priceline and TerryWhite Chemmart commonly dispense generics and can order branded imports if requested.

Online Australian pharmacies and telehealth services offer e‑prescriptions and home delivery across the country.

In our online pharmacy, tazorac is available without a prescription, with discreet delivery to Australia in 5-14 days.

Prices vary where PBS subsidy is not available; expect different private price bands depending on pack size and supplier.

Rural patients may face slightly longer delivery times due to freight and stock lead times.

Procurement pathways include in‑store purchase on private script, online pharmacy ordering and telehealth e‑prescription dispensing with courier delivery.

Short table: Pack Size And Typical Private Price Bands (Indicative)

Comparable Medicines And Preferences

What are reasonable alternatives and why might a clinician choose them?

Adapalene, available as OTC and prescription products, is often chosen for mild to moderate acne because of better tolerability and easier access.

Tretinoin remains a prescription option for acne and photoageing and is selected based on clinician experience and PBS access.

For plaque psoriasis, topical corticosteroids and calcipotriol are established options and combination approaches can improve outcomes beyond monotherapy.

Tazarotene has the advantage of selective RAR‑β and RAR‑γ activity, which alters keratinocyte gene expression and gives a strong keratolytic effect.

Downsides are the higher irritation potential and the strict contraindication in pregnancy.

Comparative table: Efficacy, Tolerability, PBS Status

Frequently Asked Questions

Q: Is tazarotene safe in pregnancy?

A: No.

A: Tazarotene is an absolute contraindication in pregnancy due to teratogenic risk and should be stopped if pregnancy is confirmed.

Q: How soon will I see results?

A: Some patients notice improvement by four weeks with maximal benefit usually at eight to twelve weeks.

Q: Can I use sunscreen and moisturiser?

A: Yes.

A: Sunscreen daily and regular moisturiser use are essential to reduce photosensitivity and control irritation; apply moisturiser as needed and sunscreen in the morning.

Q: Where can I get it in rural areas?

A: Telehealth e‑prescription plus local pharmacy dispensing or courier delivery from major chains is a reliable route.

Data highlight: age indications are ≥12 years for acne and ≥17 years for psoriasis — confirm age before prescribing.

Guidelines For Proper Use

What should pharmacists tell patients at dispensing and how should the product be stored?

Confirm the indication, age and pregnancy status before supply and advise once‑daily evening application of a thin layer.

Recommend starting at 0.05% for sensitive skin and provide a step‑up plan if necessary.

Emphasise pairing with a gentle moisturiser and daily broad‑spectrum SPF to manage photosensitivity and irritation.

Document counselling notes in the pharmacy record and schedule follow‑up at two to four weeks for early assessment.

For rural patients, coordinate telehealth reviews and local skin checks if severe irritation develops.

Storage instructions: store between 20–25°C, do not freeze, protect from excessive heat and light and keep caps tightly closed.

Pharmacist script template for telehealth (brief): confirm patient details and pregnancy status, state indication and planned follow‑up, note strength and quantity, sign and supply as private prescription where PBS not available.

Delivery Across Australia